Navigation Links
Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment
Date:5/19/2010

SOUTH SAN FRANCISCO, Calif., May 19 /PRNewswire/ -- A meta-analysis of approximately 80,000 individuals from 32 prospective studies was published in The Lancet on May 1, 2010. The data shows that elevated levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme, are associated with an increased risk of coronary heart disease similar in magnitude to that with non-HDL cholesterol or systolic blood pressure. The analysis by the Lp-PLA2 Studies Collaboration entitled, "Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies," was led by Drs. Alexander Thompson and John Danesh of The University of Cambridge, England.

"More than 600,000 deaths occur annually as a result of coronary heart disease. Risk factors such as smoking, diabetes, high blood pressure and increased levels of LDL or 'bad' cholesterol often fail to account for coronary heart disease in patients," said Dr. Peter Toth, director of Preventative Cardiology at Sterling Rock Falls Clinic in Illinois, who was not involved in the study. "This data further demonstrates the benefit of measuring Lp-PLA2 levels to better determine a patient's risk of suffering a heart attack or ischemic stroke that is not readily apparent by traditional risk factor assessment."

The PLAC® Test, a commercially available test that measures levels of Lp-PLA2, is the only blood test cleared by the FDA for predicting risk for coronary heart disease and ischemic stroke associated with atherosclerosis.

The full text of the study can be found on The Lancet website at:

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960319-4/fulltext.

About the PLAC® Test

The PLAC® Test is the only FDA-cleared blood test to aid in assessing risk for coronary heart disease and ischemic stroke associated with atherosclerosis. The simple blood test measures levels of a novel risk marker, lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular specific inflammatory enzyme implicated in the formation of rupture prone plaque; it is plaque rupture and thrombosis (major blood clot), not stenosis (narrowing of the arteries), that causes the vast majority of heart attacks. The PLAC Test is recommended for patients at moderate to high risk for heart attack or stroke, according to an expert panel consensus published in a June 2008 supplement to The American Journal of Cardiology.

About diaDexus

diaDexus, Inc., a privately held diagnostics company based in South San Francisco, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. For more information, visit www.plactest.com or www.diaDexus.com.    


'/>"/>
SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Largest Civil Settlement in Pharmaceutical Case Announced by U.S. Department of Justice
2. CyberKnife Radiosurgery Now Reimbursed Throughout France and Largest Italian Region
3. First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity
4. OMNIlife science, Inc., Announces U.S. Distribution Agreement with SERF-Dedienne Sante of France for its ION free Large Diameter Head Dual Mobility Acetabular Cup System
5. FDA Approves First Generic Tamsulosin to Treat Enlarged Prostate Gland
6. New York States Largest Integrated Health System Chooses Craneware Revenue Integrity Solutions
7. Russias Largest Breast Cancer Oncology Center Uses New CAD Software for Advanced Breast Cancer Detection
8. Multi-Center Data in a Large Series of Patients Show Vertebroplasty Provides Dramatic and Lasting Pain Relief for Vertebral Compression Fractures
9. One-Third of Antimalarial Medicines Sampled in Three African Nations Found to Be Substandard in Large-Scale USP-WHO Study
10. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
11. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)...  Montoya Love is recognized by Continental Who,s Who ... Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range of ... healthcare institutions, clinical laboratories and life science researchers with ... globe. ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 06, 2016 , ... Shark Finds and Kevin Harrington, along with ... DRTV campaign with Belly Bands. , Having a dog is great—except when it wets ... and find nothing works, get Belly Bands, the easiest way to stop dogs ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, ... much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on ... week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s Day gift for ... your toes. Foot massage, whether administered by a professional masseuse or a loved one, ... American Board of Multiple Specialties in Podiatry (ABMSP) has taken the upcoming Valentine’s ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... from across the country gathered at the La Valencia Hotel in San Diego, ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a leading ... Software & Services for HIT Implementation Support & Staffing report with an outstanding ... performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 ...
Breaking Medicine News(10 mins):